Biotech Development Costs Higher Than Pharmaceuticals
A recent study by the Tufts Center for the Study of Drug Development (CSDD, http:csdd.tufts.edu) shows that development costs are higher for biotechnology products than previously estimated development costs for traditional pharmaceuticals.
A recent study by the Tufts Center for the Study of Drug Development (CSDD, csdd.tufts.edu) shows that development costs are higher for biotechnology products than previously estimated development costs for traditional pharmaceuticals. The study estimates the average cost of developing a new biotechnology product at $1.2 billion.
Tufts CSDD said the $1.2-billion estimate reflects the costs of drugs that fail in testing and the time costs associated with bringing a new biopharmaceutical to market. Of this amount, capitalized out-of-pocket preclinical costs totaled $615 million, while the cost of clinical studies totaled $626 million. Capitalized costs include both out-of-pocket and time costs. A new biotech product took 97.7 months on average to wend its way through clinical development and regulatory review, about 8% longer than for pharmaceuticals, according to the analysis.
To develop the estimates, Tufts CSDD relied on compound-specific costs for a sample of 17 investigational biopharmaceuticals from four firms that first entered clinical testing from 1990 to 2003. Average development times and phase-transition probabilities were estimated based on data from more than 500 therapeutic recombinant proteins and monoclonal antibodies. According to the study, biopharmaceuticals had an overall clinical approval success rate of 30.2%, compared to 21.5% for traditional pharmaceutical firm pipelines.
The Tufts CSDD findings were reported in the November–December Tufts CSDD Impact Report. The full study will be published in the journal Managerial and DecisionEconomics.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
